Clinical trials: Naltrexone
Borderline Personality Disorder, Dissociation
Naltrexone in the Treatment of Dissociative Symptoms in Patients With Borderline Personality Disorder
Our study aims at contributing to a valid appraisal of the magnitude of naltrexone efficacy as an antidissociative agent by using a double-blind randomized controlled trial.
- Trial name
- NCT01133301
- Testing
- Naltrexone
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Central Institute of Mental Health, Mannheim
Healthy
Endophenotype for Alcohol Misuse in Healthy Minority Populations
The purpose of the study is to understand the relationship between what an individual inherited from their family (genetics), how they respond and feel after drinking alcohol, and how they respond to pre-treatment with…
- Trial name
- DEFINE (NCT00256451)
- Testing
- Naltrexone, alcohol
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Obesity, Overweight
A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes
The purpose of this study is determine whether the combination of naltrexone SR and bupropion SR is safe and effective in treating obesity in subjects with type 2 diabetes.
- Conditions
- Obesity, Overweight, Diabetes Mellitus, Type 2
- Trial name
- NCT00474630
- Testing
- Naltrexone SR 32 mg/bupropion SR 360 mg/ day, Ancillary therapy
- Where
- 53 sites in United States
- Volunteers
- 505 people
- Sponsor
- Orexigen Therapeutics, Inc
Melanoma, Prostate Cancer
Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer
will scientifically evaluate whether Low Dose Naltrexone (LDN) has activity in refractory solid tumors within the context of a phase II clinical study
- Conditions
- Melanoma, Prostate Cancer, Renal Cancer
- Trial name
- NCT01650350
- Testing
- Naltrexone
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Brown University
Opiate Dependence
Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence
The purpose of this study is to evaluate a very low dose naltrexone-buprenorphine treatment to transfer opioid dependent individuals to extended release naltrexone injection (Vivitrol).
- Trial name
- BUP/NXT-VIVI (NCT01690546)
- Testing
- very low dose naltrexone, extended release naltrexone, buprenorphine/naloxone
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Paolo Mannelli
Fibromyalgia
LDN and tDCS in Fibromyalgia
Fibromyalgia is a complex generalized and diffuse musculoskeletal chronic pain; and pharmacological approaches are widely used to relieve pain and increase life quality.
- Trial name
- NCT04502251
- Testing
- Low-Dose Naltrexone, Transcranial Direct Current Stimulation
- Where
- Brazil
- Volunteers
- 92 people
- Sponsor
- Centro Universitario La Salle
Substance Use Disorders, Substance Abuse
Can The Bridge Transition Opiate Use Disorder Patients in Stable Recovery From Buprenorphine to Naltrexone
This is an open-label, single center study of The Bridge in patients with sustained remission of opiate dependence on established, low-dose MAT with buprenorphine. A fixed number of patients will be admitted to the study.
- Conditions
- Substance Use Disorders, Substance Abuse, Substance Use, Substance Dependence
- Trial name
- NCT03762798
- Testing
- The Bridge
- Where
- United States
- Sponsor
- The Cleveland Clinic
Depression
The Safety and Efficacy of Naltrexone and Scopolamine Utilized in the Treatment of Major Depression
The purpose of this clinical trial is to determine the safety and efficacy of scopolamine utilized in conjunction with naltrexone for the treatment of major depression.
- Trial name
- NCT03386448
- Testing
- Scopolamine and naltrexone
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- The Taub Group
Healthy
Bioequivalence Study Comparing Naltrexone SR/Bupropion SR Trilayer Tablets From Two Manufacturers
This is a Phase 1, open-label, randomized, single-dose, 2-way crossover study in healthy adult subjects to assess the bioequivalence of naltrexone SR/bupropion SR combination trilayer tablets prepared at two different…
- Trial name
- NCT02259179
- Testing
- Reference naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets), Test naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Orexigen Therapeutics, Inc
Opiate Dependence, Human Immunodeficiency Virus
Opioid Relapse & HIV Risk: 48 Versus 24 Weeks of Injectable Extended Release Naltrexone
To address the question of the comparison of two courses of Vivitrol with differing lengths in 130 HIV negative, consenting, opioid addicted patients who have completed inpatient treatment.
- Trial name
- NCT01882361
- Testing
- injectable naltrexone
- Where
- Russia
- Volunteers
- 77 people
- Sponsor
- University of Pennsylvania
Pathological Gambling
Investigation of Naltrexone for Pathological Gambling
The investigators plan to investigate the safety, tolerability, and efficacy of the opioid antagonist naltrexone in Pathological Gambling.
- Trial name
- NCT01057862
- Testing
- Naltrexone
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Yale University
Alcohol Dependence
Pharmacogenetic Response to Naltrexone For Alcohol Dependence
The aims of the study are to test for treatment outcome differences in alcohol dependent subjects randomly assigned to 12 weeks of treatment with NTX (50mg/day) or placebo among those with one or two copies of the Asp40 allele of…
- Trial name
- NCT00831272
- Testing
- naltrexone
- Where
- 4 sites in United States
- Volunteers
- 221 people
- Sponsor
- David Oslin
Alcohol Dependence
Pharmacotherapy for Alcohol Dependence in Convicted Drinking Drivers
This pilot study will explore the ways to link Ontario's remedial system for convicted drinking drivers to medical intervention, assess the receptiveness of the Back on Track client population to effective medical interventions…
- Trial name
- NCT01638377
- Testing
- Naltrexone, Control
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- Centre for Addiction and Mental Health
Opiate Dependence, HIV Infections
HIV Risk Reduction and Drug Abuse Treatment in Iran
A randomized, double blind clinical trial comparing buprenorphine and naltrexone maintenance treatment when combined with drug abuse and HIV risk reduction counseling (DC-HIV) for heroin and opium addicts in Iran.
- Trial name
- NCT00398008
- Testing
- Buprenorphine/Subutex, Naltrexone, Drug counseling
- Where
- 2 sites in United States, Iran
- Sponsor
- Yale University
Major Depressive Disorder, Alcohol Use Disorder
Naltrexone Plus Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder
To evaluate if naltrexone plus ketamine is effective in reducing depression and alcohol consumption.
- Trial name
- NCT03658330
- Testing
- Ketamine + Naltrexone
- Volunteers
- 5 people
- Sponsor
- VA Connecticut Healthcare System
Bipolar Disorders, Schizophrenia
Injectable Versus Oral Naltrexone Treatment of Alcohol Dependence In Serious Mental Illness (SMI)
The primary aim of this study is to determine the feasibility of long-acting injectable naltrexone administration in a clinical trial in patients with SMI who also have a diagnosis of alcohol dependence.
- Conditions
- Bipolar Disorders, Schizophrenia, Schizoaffective Disorders, Alcohol Dependence
- Trial name
- vivitrol (NCT00453804)
- Testing
- injectable naltrexone, oral naltrexone
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- State University of New York - Upstate Medical University
Alcohol Drinking
Kappa-PET Imaging and Naltrexone in Alcohol Drinking Behaviors
The primary purpose of the study is to increase our knowledge of receptor function in the brains of people who are heavy drinkers and taking naltrexone (NTX), a medication that has been approved for the treatment of alcohol…
- Trial name
- NCT01625611
- Testing
- Naltrexone
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Yale University
Methamphetamine-dependence, Methamphetamine Abuse
Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder
The primary objective of this study is to evaluate the efficacy of extended release naltrexone plus bupropion XL (XR-NTX/BUP-XL) compared to matched injectable and oral placebo (iPLB/oPLB) in reducing methamphetamine (MA) use in…
- Trial name
- NCT06233799
- Testing
- extended-release naltrexone (XR-NTX), extended release bupropion (BUP-XL) tablets (BUP-XL), iPLB
- Where
- 11 sites in United States
- Volunteers
- 360 people
- Sponsor
- National Institute on Drug Abuse (NIDA)
Cocaine Dependence
Cocaine Use Reduction With Buprenorphine
The aim of this study is to investigate the safety and effectiveness of buprenorphine in the presence of naltrexone for the treatment of cocaine dependence.
- Trial name
- CURB (NCT01402492)
- Testing
- Buprenorphine + Naltrexone
- Where
- 11 sites in United States
- Volunteers
- 302 people
- Sponsor
- University of California, Los Angeles
Alcohol-Related Disorders, Alcoholism
Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1
Many cocaine dependent individuals are also dependent on alcohol. Such individuals respond poorly to existing treatments and have received little research attention in the past.
- Conditions
- Alcohol-Related Disorders, Alcoholism, Cocaine-Related Disorders
- Trial name
- NCT00142844
- Testing
- Naltrexone, Disulfiram
- Where
- United States
- Volunteers
- 208 people
- Sponsor
- University of Pennsylvania